YoY Growth Masks the Real Story—Sequential Collapse and Aquapharm's Deferred Promise
PCBL posted 14% revenue and 20% profit growth year-on-year. But a 52% sequential profit drop, Aquapharm's massive ₹75 crore target deferral, and deliberate export pullback tell a different story: demand is weaker than the headline suggests, and execution risk is material.
₹2,474 Cr
+14.4% (supported by pricing discipline)
₹74 Cr
+20.2% but QoQ: -52.1%
~₹17,500
double-digit FY26 improvement on track
3.0%
below expectation given revenue growth
The headline is clean: ₹2,474 crore revenue (+14.4% YoY), ₹74 crore profit (+20.2% YoY), ₹310 crore EBITDA (+12% YoY). But the quarter's real story lives in the gaps. A -52% sequential profit collapse tells you Q1 was soft and Q2 margin improvement ran into headwinds. Aquapharm's ₹42 crore EBITDA is a 56% miss on the prior ₹75 crore quarterly target—which management quietly deferred without offering a new one. Export volumes fell 18% QoQ, a deliberate pullback to protect margins as Southeast Asia customers grew cautious. The market saw through it: the day-1 sell-off of -2.32% held firm; by day 3, the stock had recovered only +0.28%, signaling conviction remained weak.
The claims, and what holds up
Consolidated revenue grew 14% YoY
₹2,474.4 Cr, +14.4% YoY; flat QoQ reveals weak Q1 and stable Q2 pricing
Supported
Profit after tax grew 20% YoY
₹74.1 Cr, +20.2% YoY but -52.1% QoQ; sequential collapse concerning
Supported (headline) / Overstated (quality)
Aquapharm targeting double-digit H2 growth
Q2 EBITDA ₹42 Cr; prior ₹75 Cr quarterly target abandoned, not reiterated
Contradicted
Export volume recovery on track
Exports -18% QoQ; pulled back deliberately on margin pressure, not demand strength
Overstated
EBITDA/tonne double-digit improvement vs FY26 maintained
Current ₹17,500/tonne (post-tariff adjustment) vs ₹16,500–17,000 FY26 base; reaffirmed
Supported
What changed on this call
Aquapharm ₹75 Cr quarterly EBITDA target deferred (was prior guidance)
Volume growth guidance downgraded: 'high single-digit' → 'challenging'
EBITDA/tonne double-digit improvement over FY26 reaffirmed (₹16,500–17,000 base)
Pricing discipline prioritized over volume chase; spot prices firming Nov–Dec expected
The Aquapharm deferral is the pivot. Last quarter, management cited a ₹75 crore quarterly EBITDA target. Q2 delivered ₹42 crore. Rather than reset expectations, the new CEO deferred the entire target, citing need for 'deeper analysis.' On the call, H2 growth is now guided as 'double-digit' without magnitude—a soft downgrade masquerading as 'new product focus' (PBTC, GLDA, Green Chelates). Export pullback, nominally about 'margin discipline,' is demand-driven: customers in Southeast Asia are holding lean inventory due to crude price uncertainty and geopolitical caution. Volume guidance softening from 'high single-digit' to 'challenging' is an admission that macro headwinds are deeper than previously assumed.
How the market is positioned
The stock entered earnings at ₹282.6. The day-1 sell-off of -2.32% (on 50.7% institutional delivery) represents a clear rejection of the story. By day 3, the stock had recovered only +0.28%—the move did not hold. Current price of ₹283.4 is 51.51% below its all-time high of ₹584.4, and trades below all key moving averages (SMA20 ₹294.61, SMA50 ₹314.32, SMA200 ₹299.2). The stock sits 25.12% above its 52-week low but remains deeply depressed relative to its prior range. RSI at 39.6 is neutral; no panic, but no conviction either.
₹283.4
as of Nov 5
-51.51%
Major multi-year drawdown
Below SMA20/50/200
Downtrend intact
5.79%
up 0.23pp QoQ; steady, not accumulating
Institutional activity is tepid. FII at 5.79% (up only 0.23pp QoQ) and DII at 11.27% (up 0.29pp) suggest neither conviction nor panic—institutions are watching, not buying. Promoter holding is stable at 53.38%. Bulk activity in July (₹358–359/share via MICROCURVES TRADING) appears to be market-making, not significant. The lack of institutional accumulation despite a 50%+ drawdown signals the market is skeptical of the turnaround story on offer.
The bull-bear ledger
YoY revenue (+14.4%) and PAT (+20.2%) growth is organic, not one-time driven
Pricing discipline delivered; spot prices firming supports H2 margin recovery
Tyre OEM expansion in India is a structural tailwind; Carbon Black demand supportive
Battery materials (silicon carbon via Nanovace, 51% JV) and specialty grades position for high-growth adjacencies
Sequential PAT collapse (-52% QoQ) signals execution slippage and weak Q1
Aquapharm ₹75 Cr quarterly target deferred; no replacement guidance; confidence in remediation unclear
Export volumes down 18% QoQ; 'margin discipline' is demand-driven, not strategic
NPM of 3.0% is below expectations; suggests leverage and profitability headwinds
Volume growth guidance downgraded from 'high single-digit' to 'challenging'; macro caution high
Customer inventory destocking ongoing; recovery timing uncertain
Risks, ranked by how much they should concern a holder
Aquapharm execution risk—target deferred, new CEO analyzing business
HighAquapharm was supposed to deliver ₹75 Cr EBITDA quarterly. Q2 was ₹42 Cr (56% miss). Target now deferred; no new reset offered. Remediation unclear. If H2 doesn't hit 'double-digit growth,' the subsidiary remains a drag.
Sequential margin collapse signals deeper demand weakness
High-52% QoQ PAT despite flat revenue and pricing gains means Q1 was very weak and Q2 margin expansion failed. If volumes don't recover and customer caution persists, H2 guidance could face downward pressure.
Geopolitical & tariff escalation—U.S.-India negotiations ongoing
MediumTariff uncertainty delays customer sourcing decisions. Export volumes are already down 18%. If U.S. tariffs materialize or trade wars intensify, export recovery (now deferred to FY28) could slip further. PCBL received ₹33 Cr tariff refunds YTD; loss of these would hit margins.
Volume growth downgrade—demand softer than prior expectations
MediumGuidance shifted from 'high single-digit' to 'challenging.' Macro caution (crude volatility, customer destocking) is reducing near-term ordering. If inventory recovery is slower or customer confidence doesn't improve, FY27 volume target could be missed.
Specialty Carbon Black feedstock constraint—limits upside
MediumSpecialty CB capacity is ~75 tonnes and feedstock-constrained. Potential upside is 300% but bottlenecked by raw material sourcing. If suppliers don't ramp or costs spike, the Specialty CB story remains a long-term play, not a near-term catalyst.
The debate
What to watch next
1 · Aquapharm's H2 EBITDA and new product ramp (Q3 forward)
If Aquapharm delivers 'double-digit H2 growth' (guidance is vague on magnitude), PCBL's execution story stabilizes. If H2 EBITDA is in the ₹45–50 Cr range or lower, the subsidiary remains a drag and confidence suffers. Watch for PBTC, GLDA, Green Chelates revenue contribution and margins.
2 · Export volume recovery and customer inventory normalization (Q3–Q4)
Exports are down 18% QoQ due to deliberate pullback. If customer orders normalize and export volumes snap back to flat or modest growth, it signals demand recovery. If exports remain down or decline further, macro weakness is deeper than management assumes.
3 · Specialty Carbon Black feedstock sourcing and Line 6 ramp
Specialty CB is a growth engine but feedstock-constrained. Progress on Line 6 commercialization and new feedstock sourcing (diversifying from Gulf CBFS to U.S., Korea, Malaysia, Thailand) will determine whether this segment becomes a material margin accretive driver or remains a long-term story.
PCBL is a steady, profitable carbon black producer with genuine long-term structural tailwinds (tyre expansion, battery materials, supply constraints). But this quarter is not a step-change; it is a consolidation marked by demand caution, execution risk, and sequential margin compression. YoY growth is real and organic, but sequential stagnation and guidance withdrawals signal near-term momentum is fading.
The market's -2.32% day-1 sell-off and failure to recover is the right read. Hold, don't accumulate. The number to track is not YoY PAT growth (which inflation and base effects can flatter), but sequential EBITDA/tonne and Aquapharm's Q3–Q4 EBITDA run-rate. If those stabilize and export volumes recover, PCBL's 2027 thesis improves. Until then, execution risk is material.
Informational and educational content only. Not investment advice.